Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.

Also called NCT02496000

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 188 participants (enrolled count) (from the registry)
Sponsor
  • Integrium Registry lists this organization as a collaborator
  • Oramed, Ltd. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02496000
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02496000. Randomized; quadruple masking; primary purpose treatment. Start 2015-07-27 (actual); primary completion 2016-06-27 (actual). Results posted on 2017-02-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Condition
Diabetes Type 2
Intervention (Drug)
ORMD-0801
Intervention (Drug)
Placebo Comparator
Lead sponsor
Oramed, Ltd. (class: industry)
Collaborator
Integrium (class: industry)

Record details

Record id
cardio:ct-nct02496000
Content hash
a12b778a3b1a340f1d687875719d91d0c1442bbb4cae04a99f7ecaf8400b0a0a